Shiegnitz et al. examined serum GDF15 from OSCC patients before treatment and healthy controls: as previously demonstrated in other malignancies (e.g., CRC and prostate cancer), serum GDF15 concentration was significantly higher in OSCC patients. This evidence concerns the gene GDF15 and prostate cancer.